A Phase 3 interventional study of lamotrigine, 300 mg/day and lamotrigine, 250 mg/day in Epilepsy, Partial, sponsored by GlaxoSmithKline. Completed at 103 sites in 8 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-01-02.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.
Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 26th largest by enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2006, is one of 31 in phase 3, and was the 25th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 34 · Phase 4 9
First in 1992; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 86 interventional studies, 100 across the 16 observational. Of the 73 that completed or were terminated, 37 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 102 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 7 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Partial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07505004Phase 3Praxis Precision MedicinesRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | 2027-01 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT05673915Mayo ClinicStudy of Transcranial Direct Current Stimulation to Treat Epilepsy | 2026-12 |
| NCT05794295University of California, DavisSleep Architecture & Cognition in Focal Epilepsy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies in Epilepsies, Partial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
The study consists of a Treatment phase, where efficacy is determined and a Continuation phase for extended safety information. The Continuation phase is open to all Treatment phase participants and those who did not qualify for treatment because of an insufficient number of seizures during the Baseline phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE: With prior authorization from GlaxoSmithKline (GSK), retrospective data may take the place of up to the first 4 weeks (i.e., first 28 days) of the Baseline Phase for subjects providing reliable documentation of the following:
All subjects permitted to use retrospective baseline data must complete a minimum of four weeks (i.e., 28 days) of the prospective Baseline Phase. The retrospective plus the prospective Baseline Phases must equal the 56 consecutive days prior to the start of dosing with study drug.
if female, and of be using an acceptable form of , to include one of the following:
Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject.
Any intrauterine device (IUD) with a documented failure rate of less than 1% per year
Double barrier method consisting of spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm).
NOTE: Women who have had a hysterectomy, tubal ligation, or are are considered to be of non-childbearing potential.
NOTE: A pharmacokinetic interaction has been observed between lamotrigine (LTG) and estrogen-based oral contraceptives. Therefore, the use of hormonal therapy (e.g., for contraception or hormone replacement therapy) is not allowed.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg/day treatment
Drug: lamotrigine, 300 mg/day
250 mg/day treatment
Drug: lamotrigine, 250 mg/day
Drug page: Lamotrigine
300 mg/day
Also known as: lamotrigine
Drug page: Lamotrigine
250 mg/day
The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study.
Time frame: From Study Visit 5 through Visit 9 of the Treatment Phase (approximately Week 7 through Week 23)
The Percentage of Participants in the 250 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who had reached Visit 5 minus major protocol violators. The Control group was composed of data from other similar studies and is not part of this study.
Time frame: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
Time to Discontinuation in the Treatment Phase
Time (days) until the participant discontinued the study
Time frame: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
Percentage of Participants Meeting Escape Criteria in the Treatment Phase
The percentage of participants meeting Escape Criteria was calculated as the number of participants who met an Escape Criterion divided by the number who had reached Visit 5 minus major protocol violators. Escape Criteria are: (1) doubling of average monthly seizure frequency; (2) doubling of the highest consecutive 2-day seizure total; (3) occurrence of a new, more severe seizure type; or (4) worsening of generalized tonic-clonic seizures.
Time frame: Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
Percent Change From Baseline in Weekly Seizure Frequency Between Study Visits 3 (Start of Dosing) and 9 (End of the Treatment Phase)
Change from Baseline was measured as the number of seizures at Visits 3 through 9 minus the number of seizures at Baseline. The number of partial seizures during treatment divided by the number of weeks of treatment was compared to the weekly seizure frequency during Baseline. A positive number equals a reduction in seizure frequency.
Time frame: Baseline and Study Visit 3 through Visit 9 of the Treatment phase (Treatment Week 0 through Week 23)
Number of Seizure-free Participants During the Last 12 Weeks of Treatment of the Treatment Phase
The number of participants who had no seizures during the treatment period was calculated. The last 12 weeks of treatment were either Weeks 11-22 or 12-23 depending on which background AED was being withdrawn
Time frame: The last 12 weeks of treatment of the Treatment phase (Monotherapy phase - approximately Week 11 through Week 23)
Percent Change From Baseline in the Average Seizure Frequency Measured at the End of Participation in the Continuation Phase
Change from baseline was calculated as the average seizure frequency at the end of the Continuation Phase minus the average seizure frequency at Baseline. The number of seizures during the Continuation phase divided by the number of weeks was compared to the number of seizures at Baseline. A positive number indicates a reduction in seizure frequency.
Time frame: Baseline and start of Continuation phase through Week 24 or end of participation in the Continuation phase
The Number of Participants With at Least the Specified Change in Seizure Frequency, Compared to Baseline, at the End of Participation in the Continuation Phase (Maximum of 24 Weeks)
Change in seizure frequency was calculated as the average seizure frequency during the Continuation Phase minus the seizure frequency at Baseline.
Time frame: Baseline and entire Continuation phase (24 Weeks)
All participants in the Treatment phase and all Baseline Failure participants are eligible to enter the Continuation phase. The Continuation phase is for long-term safety exposure to lamotrigine extended release (LTG XR) at 300 mg/day; it is not a cross-over phase.
| Milestone | Lamotrigine Extended-release (LTG XR), 300 mg | LTG XR, 250 mg | Baseline Failures |
|---|---|---|---|
| Started | 113 | 113 | 0 |
| Completed | 94 | 79 | 0 |
| Not completed | 19 | 34 | 0 |
| Withdrew: Adverse event | 4 | 10 | 0 |
| Withdrew: Withdrawal by subject | 9 | 8 | 0 |
| Withdrew: Lack of efficacy | 6 | 7 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 0 |
| Withdrew: Protocol violation | 0 | 4 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Milestone | Lamotrigine Extended-release (LTG XR), 300 mg | LTG XR, 250 mg | Baseline Failures |
|---|---|---|---|
| Started | 184 | 0 | 11 |
| Completed | 160 | 0 | 8 |
| Not completed | 24 | 0 | 3 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 0 | 0 |
| Withdrew: Site closed by sponsor | 8 | 0 | 0 |
| Withdrew: Scheduling error | 1 | 0 | 0 |
| Withdrew: Ran out of drug due to travel | 1 | 0 | 0 |
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study.
| percentage of participants | Lamotrigine Extended-release (LTG XR), 300 mg |
|---|---|
| The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase) | 12 |
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who had reached Visit 5 minus major protocol violators. The Control group was composed of data from other similar studies and is not part of this study.
| percentage of participants | LTG XR, 250 mg |
|---|---|
| The Percentage of Participants in the 250 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase) | 16 |
Time (days) until the participant discontinued the study
| Days | Lamotrigine Extended-release (LTG XR), 300 mg | LTG XR, 250 mg |
|---|---|---|
| Time to Discontinuation in the Treatment Phase | 147.3 ± 31.5 | 133.2 ± 45.6 |
The percentage of participants meeting Escape Criteria was calculated as the number of participants who met an Escape Criterion divided by the number who had reached Visit 5 minus major protocol violators. Escape Criteria are: (1) doubling of average monthly seizure frequency; (2) doubling of the highest consecutive 2-day seizure total; (3) occurrence of a new, more severe seizure type; or (4) worsening of generalized tonic-clonic seizures.
| percentage of participants | Lamotrigine Extended-release (LTG XR), 300 mg | LTG XR, 250 mg |
|---|---|---|
| Percentage of Participants Meeting Escape Criteria in the Treatment Phase | 4 | 6 |
Change from Baseline was measured as the number of seizures at Visits 3 through 9 minus the number of seizures at Baseline. The number of partial seizures during treatment divided by the number of weeks of treatment was compared to the weekly seizure frequency during Baseline. A positive number equals a reduction in seizure frequency.
| percent change in seizures | Lamotrigine Extended-release (LTG XR), 300 mg | LTG XR, 250 mg |
|---|---|---|
| Percent Change From Baseline in Weekly Seizure Frequency Between Study Visits 3 (Start of Dosing) and 9 (End of the Treatment Phase) | 54.8 (-124.5 to 100.0) | 52.2 (-221.3 to 100.0) |
The number of participants who had no seizures during the treatment period was calculated. The last 12 weeks of treatment were either Weeks 11-22 or 12-23 depending on which background AED was being withdrawn
| participants | Lamotrigine Extended-release (LTG XR), 300 mg | LTG XR, 250 mg |
|---|---|---|
| Number of Seizure-free Participants During the Last 12 Weeks of Treatment of the Treatment Phase | 22 | 8 |
Change from baseline was calculated as the average seizure frequency at the end of the Continuation Phase minus the average seizure frequency at Baseline. The number of seizures during the Continuation phase divided by the number of weeks was compared to the number of seizures at Baseline. A positive number indicates a reduction in seizure frequency.
| percent change in seizures | Lamotrigine Extended-release (LTG XR), 300 mg | Baseline Failures |
|---|---|---|
| Percent Change From Baseline in the Average Seizure Frequency Measured at the End of Participation in the Continuation Phase | 72.2 (-840.7 to 100.0) | 68.8 (-111 to 100) |
Change in seizure frequency was calculated as the average seizure frequency during the Continuation Phase minus the seizure frequency at Baseline.
| participants | Lamotrigine Extended-release (LTG XR), 300 mg | Baseline Failures |
|---|---|---|
| At least a 25% reduction in seizures | 169 | 7 |
| At least a 50% reduction in seizures | 137 | 6 |
| At least a 75% reduction in seizures | 85 | 3 |
| 100% reduction in seizures | 38 | 2 |
| At least a 50% increase in seizures | 6 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Phase: LTG XR, 300 mg | — | 3/112 (2.7%) | 44/112 (39.3%) |
| Treatment Phase: LTG XR, 250 mg | — | 5/111 (4.5%) | 52/111 (46.8%) |
| Continuation Phase: LTG XR, 300 mg | — | 3/184 (1.6%) | 47/184 (25.5%) |
| Continuation Phase: Baseline Failures | — | 1/11 (9.1%) | 4/11 (36.4%) |
| Event | Treatment Phase: LTG XR, 300 mg | Treatment Phase: LTG XR, 250 mg | Continuation Phase: LTG XR, 300 mg | Continuation Phase: Baseline Failures |
|---|---|---|---|---|
| Status epilepticusNervous system disorders | 0/112 | 0/111 | 0/184 | 1/11 |
| ConcussionInjury, poisoning and procedural complications | 0/112 | 1/111 | 0/184 | 0/11 |
| FeverGeneral disorders | 0/112 | 1/111 | 0/184 | 0/11 |
| Generalized seizureNervous system disorders | 0/112 | 1/111 | 0/184 | 0/11 |
| Liver CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/112 | 1/111 | 0/184 | 0/11 |
| RashSkin and subcutaneous tissue disorders | 0/112 | 1/111 | 0/184 | 0/11 |
| Upper GI bleedingGastrointestinal disorders | 0/112 | 1/111 | 0/184 | 0/11 |
| Brain cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/112 | 0/111 | 0/184 | 0/11 |
| Grand mal seizureNervous system disorders | 1/112 | 0/111 | 0/184 | 0/11 |
| Head InjuryInjury, poisoning and procedural complications | 1/112 | 0/111 | 1/184 | 0/11 |
| Event | Treatment Phase: LTG XR, 300 mg | Treatment Phase: LTG XR, 250 mg | Continuation Phase: LTG XR, 300 mg | Continuation Phase: Baseline Failures |
|---|---|---|---|---|
| HeadacheNervous system disorders | 29/112 | 31/111 | 33/184 | 1/11 |
| DizzinessNervous system disorders | 12/112 | 10/111 | 11/184 | 2/11 |
| RashSkin and subcutaneous tissue disorders | 4/112 | 12/111 | 0/184 | 0/11 |
| Back painMusculoskeletal and connective tissue disorders | 0/112 | 0/111 | 5/184 | 1/11 |
| NauseaGastrointestinal disorders | 6/112 | 6/111 | 6/184 | 1/11 |
| SomnolenceNervous system disorders | 5/112 | 6/111 | 5/184 | 1/11 |
| NasalpharyngitisInfections and infestations | 7/112 | 7/111 | 5/184 | 0/11 |
| InsomniaPsychiatric disorders | 0/112 | 5/111 | 0/184 | 0/11 |
| Age, Continuous(years) | Treatment Phase: LTG XR, 300 mg | Treatment Phase: LTG XR, 250 mg | Total |
|---|---|---|---|
| Mean | 33.8 ± 14.3 | 32.9 ± 12.6 | 33.4 ± 13.5 |
| Gender(Participants) | Treatment Phase: LTG XR, 300 mg | Treatment Phase: LTG XR, 250 mg | Total |
|---|---|---|---|
| Female | 56 | 66 | 122 |
| Male | 56 | 45 | 101 |
| Race/Ethnicity, Customized(participants) | Treatment Phase: LTG XR, 300 mg | Treatment Phase: LTG XR, 250 mg | Total |
|---|---|---|---|
| African American | 5 | 4 | 9 |
| Asian | 11 | 11 | 22 |
| Arabic/North African | 0 | 2 | 2 |
| White | 96 | 94 | 190 |
| Asian - Central/South Asian | 0 | 0 | 0 |
| Asian - East Asian | 0 | 0 | 0 |
| Number of participants taking indicated concurrent antiepileptic drug at study entry(participants) | Treatment Phase: LTG XR, 300 mg | Treatment Phase: LTG XR, 250 mg | Total |
|---|---|---|---|
| Valproate | 73 | 70 | 143 |
| Levetiracetam | 11 | 13 | 24 |
| Oxcarbazepine | 12 | 12 | 24 |
| Topiramate | 12 | 10 | 22 |
| Zonisamide | 3 | 5 | 8 |
| Pregabalin | 1 | 1 | 2 |
Showing the first 100 of 103 sites across 8 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine